

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

### **Final Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul><li>Company</li><li>Insmed (brensocatib)</li></ul>	<ul> <li>General</li> <li>Advisory Committee on Antimicrobial</li> </ul> Prescribing Resistance and
Patient/carer groups  Alpha-1 UK Support Group  Asthma + Lung UK  European Lung Foundation  NARA – The Breathing Charity  NTM Patient Care UK  PCD Support UK  Pulmonary Hypertension Association UK  South Asian Health Foundation  Specialised Healthcare Alliance  Healthcare professional groups  Association of Chartered Physiotherapists in Respiratory Care  Association of Respiratory Nurse Specialists  Association for Respiratory Technology and Physiology  British Geriatrics Society  British Institute of Radiology  British Paediatric Respiratory Society  British Thoracic Society  National Heart and Lung Institute  Neonatal and Paediatric Pharmacists Group  Paediatric Bronchiectasis Network UK  Primary Care Respiratory Society UK  Royal College of General Practitioners  Royal College of Nursing	Prescribing, Resistance and Healthcare Associated Infection  Antimicrobial Resistance National Action Plan Delivery Board for Human Health  All Wales Therapeutics and Toxicology Centre  Allied Health Professionals Federation  Board of Community Health Councils in Wales  British National Formulary  Care Quality Commission  Chest, Heart and Stroke Scotland  Defra Antimicrobial Resistance Coordination Group  Department of Health, Social Services and Public Safety for Northern Ireland  Healthcare Improvement Scotland  Medicines and Healthcare products Regulatory Agency  National Association of Primary Care  National Pharmacy Association  National Strategic Clinical Network for Respiratory Conditions  NHS Confederation  NHS Wales Joint Commissioning Committee  Northern Ireland Chest, Heart and Stroke Association  Scottish Medicines Consortium  Defra Antimicrobial Resistance Coordination Group

Final stakeholder list for the evaluation of brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of Paediatrics &amp; Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>Welsh Government</li> <li>Possible comparator companies</li> <li>None</li> <li>Relevant research groups</li> <li>Asthma, Allergy and Inflammation Research Charity</li> <li>Breathing Matters</li> <li>British Association for Lung Research</li> <li>BRONCH-UK</li> <li>Cochrane Airways Group</li> <li>Genomics England</li> <li>LifeArc</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

Issue date: October 2025



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.